Pheast posts early Phase 1a PHST001 data at AACR 2026
Bottom line
Pheast Therapeutics said it presented initial Phase 1a data at AACR 2026 for PHST001, its anti-CD24 macrophage checkpoint inhibitor, in patients with advanced or metastatic solid tumors. In the company’s April 17 announcement, Pheast said the first-in-human study showed PHST001 was generally well-tolerated across dose-escalation cohorts, with most treatment-related adverse events reported as Grade 1 or 2. The company also said it saw linear pharmacokinetics, higher CD24 receptor occupancy at higher doses, pharmacodynamic signs of innate immune activation, and early signals of activity including disease stabilization and tumor shrinkage. Pheast has already moved the program into Phase 1b combination cohorts, according to its press release archive and pipeline materials. (pheast.com)
Why it matters: For veterinary professionals tracking comparative oncology and immuno-oncology platform trends, this is an early but notable readout from a macrophage-directed program aimed at the CD24-Siglec10 “don’t eat me” axis. That pathway has been positioned as a way to activate innate immunity against tumors, and Pheast’s broader materials suggest the company is pursuing combinations with standard cancer therapies as well as tumor types with high CD24 expression. While these are still early human data in people, the update is relevant because macrophage biology, checkpoint signaling, and combination immunotherapy remain active areas of translational interest across oncology, including settings where durable responses remain hard to achieve. (pheast.com)
What to watch: Watch for fuller Phase 1a dataset disclosure, details from the new Phase 1b combination cohorts, and any clearer signal on which tumor types Pheast prioritizes next. (pheast.com)
Pheast Therapeutics has reported initial Phase 1a data for PHST001 at AACR 2026, offering an early clinical look at one of the more closely watched macrophage-checkpoint approaches in solid tumors. In its April 17, 2026 announcement, the company said PHST001, an IgG4 anti-CD24 antibody, showed a generally favorable tolerability profile in dose escalation, along with evidence of target engagement, innate immune activation, and early signs of anti-tumor activity. (pheast.com)
The update builds on several milestones over the past year. Pheast announced first patient dosing in the Phase 1 trial in April 2025, received FDA Fast Track designation for PHST001 in ovarian cancer in June 2025, and by March 31, 2026 said it was advancing the program into Phase 1b combination cohorts. Its pipeline page lists PHST001 as the company’s lead Phase 1 asset and identifies the ongoing study as NCT06840886, an open-label trial in adults with advanced relapsed or refractory solid tumors intended to evaluate safety, pharmacokinetics, pharmacodynamics, and early anti-tumor activity. (pheast.com)
Mechanistically, PHST001 targets CD24, which Pheast describes as a “don’t eat me” signal that helps tumor cells evade macrophage attack through the CD24-Siglec10 interaction. That biology traces back to foundational work published in Nature in 2019, which identified CD24 signaling through macrophage Siglec-10 as a target for cancer immunotherapy. Pheast’s preclinical materials have since framed PHST001 as a macrophage-activating antibody designed to restore phagocytosis and potentially broaden anti-tumor immune responses. (pheast.com)
In the new Phase 1a update, the company said most treatment-related adverse events were Grade 1 or 2, while some patients experienced transient neutrophil decreases that were described as manageable and not linked to clinical complications. Pheast also reported linear pharmacokinetics, dose-related increases in CD24 receptor occupancy, and pharmacodynamic changes consistent with innate immune activation. On efficacy, the company characterized the findings as early signs of clinical activity, specifically citing disease stabilization and tumor shrinkage, but it did not disclose response rates, tumor-specific breakdowns, or durability metrics in the press release. That makes this a promising but still preliminary dataset. (pheast.com)
Pheast paired the clinical update with new preclinical studies at AACR 2026 that, according to its pipeline materials, support activity in metastatic models and combination potential with standard-of-care chemotherapy. The company has also publicly emphasized combinations with chemotherapy, radiation, and antibody-drug conjugates in other recent corporate materials. Taken together, that suggests Pheast is positioning PHST001 not only as a monotherapy proof-of-concept program, but as a macrophage-directed backbone that could be layered onto existing oncology regimens. That is an inference based on the company’s pipeline and presentation descriptions, rather than a head-to-head clinical demonstration at this stage. (pheast.com)
Company executives used measured language in the AACR announcement. CEO Roy Maute said the data suggest PHST001 may help address the challenge of translating macrophage biology into a treatment with the right balance of activity and tolerability, while Chief Medical Officer Raphaël Rousseau said the findings begin to build the profile the company wants in a macrophage checkpoint inhibitor: tolerability, biological activity, and combination potential. Independent expert commentary on this specific AACR dataset was not readily available in the sources reviewed, so most public reaction so far appears to be coming from the company itself and trade coverage. (pheast.com)
Why it matters: For veterinary professionals, especially those following comparative oncology, the PHST001 story is less about an immediate clinical implication in animal health and more about where immuno-oncology innovation is moving. Macrophage-directed therapies are attracting attention because they may complement T-cell-focused checkpoint strategies and could matter in tumors where immune evasion is driven by the innate arm of the immune system. The relevance to veterinary medicine is translational: CD24 biology, phagocytosis, tumor microenvironment signaling, and rational combinations are all themes that can inform future comparative research, biomarker work, and partnership opportunities, even though this dataset is still early and entirely in human oncology. (pheast.com)
What to watch: The next meaningful checkpoints will be a fuller presentation of the AACR data, enrollment and design details for the Phase 1b combination cohorts, and evidence on whether PHST001’s activity clusters in CD24-high tumors such as ovarian, endometrial, or cholangiocarcinoma, which Pheast has previously highlighted as areas of interest. (pheast.com)